Announcing the Lillie and Roy Cullen Tower — an innovative, collaborative space for medical education and research. Learn more.
We are proud to share the featured speakers for the 2023 Baylor College of Medicine Alumni Reunion.
Marc L. Boom, M.D., MBA, FACP, FACHE ‘92 is president and CEO of Houston Methodist, a hospital system with more than 2,500 beds and 29,000 employees. Its flagship, Houston Methodist Hospital, has been recognized by U.S. News & World Report as an Honor Roll hospital six times and the No. 1 hospital in Texas for 11 years in a row. The System also includes a world-renowned research institute, seven community hospitals, two large physician organizations and more than 50 graduate medical education programs. Houston Methodist is affiliated with several academic institutions including Weill Cornell Medical College, New York Presbyterian Hospital and Texas A&M University.
David L. Callender, M.D., MBA, FACS ‘84, joined Memorial Hermann Health System in 2019 as president and CEO. In his role, Dr. Callender is responsible for leading and overseeing the System’s network of more than 265 hospitals, diagnostic and specialty centers, with more than 31,000 employees and 6,700 affiliated physicians. Since his appointment as president and CEO, he has guided the System in a new strategic direction focused on improving the health of Greater Houston and its surrounding communities, with a vision of creating healthier communities, now and for generations to come. Dr. Callender is committed to positioning this vision at the center of Memorial Hermann’s daily operations and overarching strategy, ensuring that the System advances the health of Houstonians by providing expanded access to care with an unmatched focus on quality, safety and service.
Paul Klotman, M.D., began serving as president, CEO and executive dean of Baylor College of Medicine on September 1, 2010. He received his B.S. degree in 1972 from the University of Michigan and his M.D. from Indiana University in 1976. He completed his medicine and nephrology training at Duke University Medical Center. He stayed at Duke as a faculty member before moving to the National Institutes of Health in 1988, where he became chief of the Molecular Medicine Section in the Laboratory of Developmental Biology. In 1993, he became chief of the Viral Pathogenesis Laboratory in the NIDR/NIH. In 1994, he moved to Mount Sinai School of Medicine as Chief of the Division of Nephrology. In 2001, he was selected to be the chair of the Samuel Bronfman Department of Medicine of the Mount Sinai School of Medicine.
Anthony William Maresso, Ph.D., is the Joseph Melnick Endowed Professor and Chair in Molecular Virology and Microbiology at Baylor College of Medicine. His research interests include vaccinology, antimicrobial resistance, wastewater epidemiology, mutagenesis, microbial ecosystems, new gene discovery and the origins of life. He is the founder of the Tailored Antibacterial and Innovative Labs for Phage Research (TAILՓR), a Baylor-based center providing personalized viral therapeutics against drug-resistant bacteria. His research program currently encompasses twenty trainees at all levels of science with extramural support totaling over $30 million since 2010. He authored the textbook “Bacterial Virulence” in 2019 and has published over 70 peer-reviewed research articles in these fields. Dr. Maresso is one of the principal investigators leading Texas’ implementation of a state-wide wastewater viral monitoring program. He co-founded a Baylor-based biotech company, Phiogen, set to launch in early 2023.
Kim C. Worley, Ph.D. ’93, PostDoc ’97, is a professor of Molecular and Human Genetics at Baylor College of Medicine. Her research interests center on building, annotating, understanding and making use of genomes. She has coordinated research in large multi-institutional international research consortia, including analysis and publication of research results for the Human Genome Project, Human Microbiome Project and comparative genomics projects for over 40 animal species. For these projects, she had a role in creating genome representations through de novo genome assembly, improving genome representation through targeted sequencing and structural variation analysis, and contributing to the understanding of genome function through analysis, annotation and computational methods.